Core Viewpoint - Haofan Bio, a leader in the domestic peptide synthesis reagent sector, has shown significant growth and is well-positioned to capitalize on the expanding global biopharmaceutical market, particularly in peptide drugs [2][6]. Financial Performance - In the first half of 2025, Haofan Bio reported a revenue of 270 million yuan, representing a year-on-year growth of 20.1%, and a net profit attributable to shareholders of 75.88 million yuan, up 15.3% year-on-year [2]. R&D and Capacity Upgrades - Following its listing on the ChiNext board in 2023, Haofan Bio has accelerated its dual upgrades in R&D and production capacity, with a 30% increase in R&D personnel and the construction of three production bases to alleviate capacity constraints [3][6]. - The company has also established a new R&D building and introduced advanced research and testing equipment [3]. Technology and Product Development - Haofan Bio has developed a comprehensive range of peptide synthesis reagents, from the first to the fourth generation, becoming one of the few global manufacturers to cover the entire series [4][5]. - The company is actively expanding its product system to include general molecular building blocks and pharmaceutical reagents for liposomes and lipid nanoparticles, with over 120 types of these reagents in small-scale research and some entering small batch production [5]. Market Opportunities and Challenges - The global peptide drug market is expected to exceed $100 billion by 2027, presenting significant opportunities for Haofan Bio, although capacity shortages remain a critical issue [6]. - The company plans to address this by acquiring Foster Pharmaceutical for 160 million yuan, which will provide additional production capacity and facilitate the transition of new products from small-scale trials to mass production [6]. Strategic Focus - Haofan Bio emphasizes a strategy of solidifying its core product quality and maintaining market position while providing comprehensive support to clients throughout their development stages [7]. - The company aims to avoid blind pursuit of trends and instead focus on steady innovation to serve the global market effectively [7].
董事长专访 | 昊帆生物朱勇：深耕多肽赛道二十载 以稳健创新服务全球市场